Table 1.
Baseline Characteristics of Cohort
| Age, y | 47.00 (34.00 to 61.00) |
| Female | 33.80 (69/204) |
| BMI, kg/m2) | 25.60 (22.90 to 28.90) |
| IBD presenta | 81.90 (167/204) |
| PSC duration, y | 8.50 (2.90 to 14.20) |
| PSC-AIH overlap | 5.90 (12/204) |
| UDCA use | 34.30 (70/204) |
| Platelets (×109/L) | 242.80 (194.00 to 285.00) |
| Platelets <150 × 109/L | 10.8 (21/195) |
| Features of portal hypertension | 31.90 (65/204) |
| APRI | 0.50 (0.30 to 0.90) |
| SAP/ULN | 1.40 (0.90 to 2.60) |
| Total bilirubin, mg/dL | 0.80 (0.50 to 1.30) |
| MELD score | 6.50 (6.40 to 7.00) |
| Mayo PSC risk score | −0.20 (−0.80 to 0.50) |
| PREsTo | 4.30 (3.30 to 8.30) |
| Baseline LSb | 2.70 (2.30 to 3.50) |
Values are median (interquartile range) or % (n/n).
AIH, autoimmune hepatitis; APRI, aspartate aminotransferase-to-platelet ratio index; BMI, body mass index; IBD, inflammatory bowel disease; LS, liver stiffness; MELD, Model for End-Stage Liver Disease; PREsTo, primary sclerosing cholangitis risk estimate tool; PSC, primary sclerosing cholangitis; SAP, serum alkaline phosphatase; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
a
Among those with inflammatory bowel disease: n = 135: ulcerative colitis; n = 29; Crohn’s disease; n = 3 (indeterminate colitis).
b
Baseline was assessed at second magnetic resonance enterography.